Dow Medical College, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi, Pakistan.
Infect Agent Cancer. 2013 May 22;8(1):17. doi: 10.1186/1750-9378-8-17.
Lung cancer is an important etiology of malignant mortality worldwide with global statistics indicating over 1 million deaths annually. Although there have been advances in cytotoxic chemotherapy, the prognosis after treatment still remains poor. Remarkably, recent studies on the molecular level are creating the possibility to hamper lung cancer by inhibiting the hedgehog pathway. Currently, hedgehog pathway inhibitors include IWP-2, cyclopamine and aprotinin. However, Vismodegib is a new upcoming prospect which has shown positive results while undergoing clinical trials. If approved, it may lead to a novel class of anti-cancer therapy for patients seeking treatment for small cell lung cancer.
肺癌是全球恶性死亡率的重要病因，全球统计数据表明每年有超过 100 万人死亡。尽管细胞毒性化疗取得了进展，但治疗后的预后仍然很差。值得注意的是，最近在分子水平上的研究为通过抑制 hedgehog 通路来阻碍肺癌的发展创造了可能性。目前，hedgehog 通路抑制剂包括 IWP-2、环巴胺和抑肽酶。然而，Vismodegib 是一种新兴的前景药物，在临床试验中已显示出积极的结果。如果获得批准，它可能为寻求治疗小细胞肺癌的患者带来一种新的抗癌治疗方法。
